ENG/中
老虎證券
行情
交易
收费
优惠与活动
帮助
TigerAI
专栏
关于
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Ohr Pharmaceutical Inc.
5.39
0.0000
成交量：
- -
成交額：
- -
市值：
1,524.96萬
市盈率：
-1.70
高：
5.39
開：
5.39
低：
5.39
收：
5.39
52周最高：
6.28
52周最低：
1.58
股本：
282.92萬
流通股本：
244.59萬
量比：
- -
換手率：
- -
股息：
- -
股息率：
- -
每股收益(TTM):
-3.1637
每股收益(LYR):
-4.6939
淨資產收益率：
-67.07%
總資產收益率：
-18.45%
市淨率：
1.69
市盈率(LYR):
-1.15
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字：
Ohr Pharmaceutical Inc.
交易所：
NASDAQ
成立時間：
- -
員工人數：
- -
公司地址：
- -
官網：
http://www.ohrpharmaceutical.com
郵編：
- -
電話：
- -
傳真：
- -
簡介：
Ohr Pharmaceutical, Inc.2009年8月4日在特拉華州註冊，Ohr Pharmaceutical, Inc.是一家製藥公司，專註於新型療法和交付技術的發展為眼部疾病的治療。公司發展管道在不同的發展階段由多個發展計劃和指示。公司鉛臨床方案，OHR-102眼藥水，是一種新的治療產品，其可以提供一種非侵入性的治療，改善視力預后，而不需要每個辦公室訪問多次注射。公司正在評估OHR-102滴眼液，在給定的組合使用Lucentis注射，在多個相的視網膜疾病的治療中，包括濕的AMD，視網膜靜脈阻塞症，增殖性糖尿病性視網膜病和糖尿病性黃斑水腫II期研究。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OHRP/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"OHRP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","market":"US","secType":"STK","nameCN":"Ohr Pharmaceutical Inc.","latestPrice":5.39,"timestamp":1562961599999,"preClose":5.39,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":2445876,"shares":2829248,"eps":-3.163664,"marketStatus":"已收盤","change":0,"latestTime":"07-12 15:59:59 EDT","open":5.39,"high":5.39,"low":5.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.163664,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":5,"symbolChange":{"newSymbol":"NBSE","executeDate":"2019-07-15"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":5.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OHRP\",,,,,undefined,":{"symbol":"OHRP","floatShares":2445876,"roa":"-18.45%","roe":"-67.07%","lyrEps":-4.693947,"shares":2829248,"dividePrice":0,"high":5.39,"amplitude":0,"preClose":5.39,"low":5.39,"week52Low":1.582,"pbRate":"1.69","week52High":6.28,"institutionHeld":0,"latestPrice":5.39,"eps":-3.163664,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.163664,"open":5.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OHRP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-07-15","symbol":"OHRP","oldSymbol":"OHRP","newSymbol":"NBSE","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1563163200000},{"market":"US","date":"2019-05-15","symbol":"OHRP","fiscalQuarterEnding":"2019/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1557892800000,"reportTimeType":"","actualEps":-0.4},{"date":"2019-02-04","symbol":"OHRP","type":"split","dateTimestamp":1549256400000,"forFactor":20,"toFactor":1},{"market":"US","date":"2018-08-14","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"","actualEps":-0.01},{"market":"US","date":"2018-05-15","symbol":"OHRP","name":"Ohr Pharmaceutical Inc.","time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OHRP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ohrpharmaceutical.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Ohr Pharmaceutical, Inc.2009年8月4日在特拉華州註冊，Ohr Pharmaceutical, Inc.是一家製藥公司，專註於新型療法和交付技術的發展為眼部疾病的治療。公司發展管道在不同的發展階段由多個發展計劃和指示。公司鉛臨床方案，OHR-102眼藥水，是一種新的治療產品，其可以提供一種非侵入性的治療，改善視力預后，而不需要每個辦公室訪問多次注射。公司正在評估OHR-102滴眼液，在給定的組合使用Lucentis注射，在多個相的視網膜疾病的治療中，包括濕的AMD，視網膜靜脈阻塞症，增殖性糖尿病性視網膜病和糖尿病性黃斑水腫II期研究。","exchange":"NASDAQ","name":"Ohr Pharmaceutical Inc.","nameEN":"Ohr Pharmaceutical"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OHRP\",market:\"US\",,,undefined,":null}}